Alexza Pharma (ALXA) Tops Q1 EPS by 49c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Alexza Reports 2015 First Quarter Financial Results
May 6, 2015 4:05 PM EDTMOUNTAIN VIEW, Calif., May 6, 2015 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended March 31, 2015. The net loss and the loss from operations for the first quarter were $0.4 million and $13.0 million, respectively, compared to $10.7 million and $8.8 million during the same quarter in 2014, respectively.  At March 31, 2015, Alexza had consolidated cash, cash equivalents, marketable securities, and restricted cash of $23.9 million.
"We continue to focus on ways in which to drive value in Alexza and our validated Staccato® platform, including continuing the development of AZ-002 (Staccato alprazolam) and... More
